GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regado Biosciences Inc (NAS:RGDO) » Definitions » ROC %

Regado Biosciences (Regado Biosciences) ROC % : -1,247.04% (As of Jun. 2016)


View and export this data going back to . Start your Free Trial

What is Regado Biosciences ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Regado Biosciences's annualized return on capital (ROC %) for the quarter that ended in Jun. 2016 was -1,247.04%.

As of today (2024-05-16), Regado Biosciences's WACC % is 0.00%. Regado Biosciences's ROC % is 0.00% (calculated using TTM income statement data). Regado Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Regado Biosciences ROC % Historical Data

The historical data trend for Regado Biosciences's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regado Biosciences ROC % Chart

Regado Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
ROC %
-378.38 -220.22 -460.58 -1,161.31 -1,880.37

Regado Biosciences Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -348.14 -711.09 -1,551.42 -1,643.46 -1,247.04

Regado Biosciences ROC % Calculation

Regado Biosciences's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2015 is calculated as:

ROC % (A: Dec. 2015 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2014 ) + Invested Capital (A: Dec. 2015 ))/ count )
=-52.858 * ( 1 - 8.13% )/( (2.876 + 2.289)/ 2 )
=-48.5606446/2.5825
=-1,880.37 %

where

Regado Biosciences's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2016 is calculated as:

ROC % (Q: Jun. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2016 ) + Invested Capital (Q: Jun. 2016 ))/ count )
=-51.8 * ( 1 - -0.63% )/( (3.51 + 4.85)/ 2 )
=-52.12634/4.18
=-1,247.04 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2016) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regado Biosciences  (NAS:RGDO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Regado Biosciences's WACC % is 0.00%. Regado Biosciences's ROC % is 0.00% (calculated using TTM income statement data). Regado Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Regado Biosciences ROC % Related Terms

Thank you for viewing the detailed overview of Regado Biosciences's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regado Biosciences (Regado Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
Executives
Domain Parters Vii L P 10 percent owner ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Associates Domain 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Kim P. Kamdar 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Patrick J Heron director 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Dp Vii Associates Lp 10 percent owner ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Jeffrey H Cooper director BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Frazier Healthcare V, Lp 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Christopher Peetz officer: Chief Financial Officer C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Regado Biosciences (Regado Biosciences) Headlines

No Headlines